Search clinical trials for: MK0457

Total 181 results

Merck Sharp & Dohme LLC

Completed

MK0457 in Patients With Leukemia (0457-003)

Myelodysplastic Syndromes | Myelogenous Leukemia, Chronic | Chronic Myelogenous Leukemia in Blast Crisis | Lymphocytic Leukemia, B Cell, Acute
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Terminated

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Terminated

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Colorectal Cancer | Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Terminated

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Hip Fracture

Germany, Norway, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Completed

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Asthma
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders
Merck Sharp & Dohme LLC

Terminated

MK0767 and Sulfonylurea Combination Study (0767-027)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia | Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Terminated

MK0354 Clinical Efficacy and Tolerability Study (0354-004)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Terminated

MK0767 in Type 2 Diabetes (0767-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study A - MK0767 Monotherapy Study

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Merck Sharp & Dohme LLC

Completed

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Anxiety Disorder (0777-022)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Prostatic Neoplasms
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Merck Sharp & Dohme LLC

Terminated

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 and Metformin Combination Study (0767-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Diabetes Mellitus, Type 2
University Medical Center Groningen

Completed

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Melanoma

Netherlands
Merck Sharp & Dohme LLC
Bristol-Myers Squibb

Terminated

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

Type 2 Diabetes Mellitus
Samsung Medical Center

Completed

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

Hepatocellular Carcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Biliary Tract Cancer

Korea, Republic of
Organon and Co

Completed

A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)

Osteoporosis
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, Belgium, Denmark, France
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Anxiety Disorder
Organon and Co

Completed

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Migraine Headache
Eli Lilly and Company
Merck Sharp & Dohme LLC

Completed

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Stage IV Non-Small Cell Lung Cancer

Spain, United States, France, Japan
Organon and Co

Completed

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Paget's Disease of Bone
Merck Sharp & Dohme LLC

Terminated

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Diabetes Mellitus, Type 2
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan

3

Subscribe